FDA

Latest News

Image credit: Crystal light | stock.adobe.com
FDA Lifts Partial Clinical Hold on Phase II Trial of Novel Tumor Infiltrating Lymphocyte Cell Therapy for NSCLC

March 5th 2024

The FDA previously halted the IOV-LUN-202 trial following reports of a grade 5 serious adverse event that may have been linked to treatment with Iovance Biotherapeutics’ novel tumor infiltrating lymphocyte cell therapy LN-145, which is being evaluated in patients with advanced non–small cell lung cancer.

Image credit: Lisa | stock.adobe.com. High grade follicular lymphoma with marginal zone differentiation. Multiple lymphocytes are undergoing mitosis. Microscopic view.
FDA Grants Priority Review to Epkinly for Follicular Lymphoma Based on Data From Phase I/II EPCORE NHL-1 Trial

February 27th 2024

Image credit: peterschreiber.media | stock.adobe.com. Motiv COPD - Lunge und Bronchien
Data from Phase III NOTUS and BOREAS Trials Lead to Priority Review of Dupixent for COPD

February 23rd 2024

Image credit: Arif Biswas | stock.adobe.com
Promising Phase I Trial Results in Acute Myeloid Leukemia Lead to Orphan Drug Designation for Ocifisertib

February 22nd 2024

FDA Approves New Biweekly Reduced Dosing of Tecvayli Based on Phase I/II MajesTEC-1 Trial Data
FDA Approves New Biweekly Reduced Dosing of Tecvayli Based on Phase I/II MajesTEC-1 Trial Data

February 21st 2024

More News

© 2024 MJH Life Sciences

All rights reserved.